Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Concizumab - Novo Nordisk

Next Previous
Drug Profile

Concizumab - Novo Nordisk

Alternative Names: ALHEMO; Alhemo; Anti-TFPI monoclonal antibody; mAb-2021; NN-7415; NNC-0172-0000-2021; NNC-0172-2021; NNC-172-2021

Latest Information Update: 31 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Class Antihaemorrhagics; Monoclonal antibodies
  • Mechanism of Action Lipoprotein-associated coagulation inhibitor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia B; Haemophilia A
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Haemophilia A; Haemophilia B
  • Phase II Haemophilia

Most Recent Events

  • 09 Dec 2023 Pharmacodynamics, pharmacokinetics, efficacy and adverse events data from a phase III explorer8 trial in Haemophilia A and Haemophilia B presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 09 Dec 2023 Pooled efficacy data from the phase III explorer7 and explorer8 trials in Haemophilia A and B presented at 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 09 Dec 2023 Pooled efficacy data from the phase III explorer7 and explorer8 trials in Haemophilia A and B presented at 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top